$LAHO ..$20 billion in mergers and acquisitions in the cell and gene therapy space, or regenerative medicine, that year, according to the Alliance for Regenerative Medicine. ..The U.S. approval of three regenerative medicines — Novartis AG's Kymriah, Gilead Sciences Inc.'s Yescarta and Spark Therapeutics Inc.'s Luxturna — in 2017 may have inspired that round of dealmaking.
..The U.S. Food and Drug Administration also noted the influx of cell and gene therapies, with Commissioner Scott Gottlieb predicting that by 2020, the agency will receive more than 200 investigational new drug applications per year. Gottlieb added in his Jan. 15 statement that the FDA has "more than 800 active cell-based or directly administered gene therapy INDs on file."
..The deal makes Universal Cells the third Seattle biotech company to be acquired in the past month. Biotech giant Celgene reached a deal to acquire Juno Therapeutics for $9 billion and Seattle Genetics will pay $614 million to acquire Cascadian Therapeutics.
..Stem cells are capable of dividing and renewing themselves for long periods. Unlike muscle cells, blood cells, or nerve cells—which do not normally replicate themselves—stem cells may replicate many times, or proliferate. A starting population of stem cells that proliferates for many months in the laboratory can yield millions of cells. If the resulting cells continue to be unspecialized, like the parent stem cells, the cells are said to be capable of long-term self-renewal.
..Stem Cell Center is the largest membership network of regenerative medicine clinics in the world, providing cutting edge care with the latest advancements in cellular therapies to patients worldwide.
News 
Market Data 
Discover 
AI
